TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRAW TRAWS PHARMA

Market Closed 05-08 16:00:00 EDT

2.18

+0.48

+28.24%

盘后2.03

-0.15-6.88%

19:59 EDT

High2.40	Low1.79	Vol89.50M
Open2.05	D1 Closing1.70	Amplitude35.88%
Mkt Cap33.03M	Tradable Cap22.58M	Total Shares15.15M
T/O196.44M	T/O Rate864.04%	Tradable Shares10.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":2.18,"timestamp":1778270400000,"preClose":1.7,"halted":0,"volume":89497525,"hourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":2.18,"latestTime":"19:59 EDT","volume":1147997,"amount":2500940.6785,"timestamp":1778284796367,"change":-0.15,"changeRate":-0.068807,"amplitude":0.105505},"delay":0,"changeRate":0.2823529411764707,"floatShares":10358000,"shares":15150700,"eps":0.834328,"marketStatus":"Market Closed","change":0.48,"latestTime":"05-08 16:00:00 EDT","open":2.05,"high":2.3999,"low":1.79,"amount":196444471.946775,"amplitude":0.358765,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.834328,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":2.05,"preClose":1.7,"latestTime":"09:29 EDT","volume":17139404,"amount":38518092.18052559,"timestamp":1778246999999,"change":0.35,"changeRate":0.205882,"amplitude":0.417647},"postHourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":2.18,"latestTime":"19:59 EDT","volume":1147997,"amount":2500940.6785,"timestamp":1778284796367,"change":-0.15,"changeRate":-0.068807,"amplitude":0.105505},"volumeRatio":713.7565515288884,"impliedVol":1.6331,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TRAW/wiki","defaultTab":"wiki","newsList":[{"id":"2634498121","title":"Traws Pharma files to sell 35.9M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2634498121","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634498121?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:46","pubTimestamp":1778280380,"startTime":"0","endTime":"0","summary":"17:05 EDT Traws Pharma (TRAW) files to sell 35.9M shares of common stock for holders Published first on TheFly – the ultimate source for real-time,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-35-9m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-35-9m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634466922","title":"Sector Update: Healthcare Stocks Lower in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2634466922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634466922?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:50","pubTimestamp":1778262622,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Healthcare Select Sector SPDR ETF  shedding 0.9%.The iShares Biotechnology ETF  was 0.4% higher.In corporate news, Zoetis  shares fell past 6% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS cut the company's price target to $99 from $130, and Jefferies to $117 from $155.Traws Pharma  shares surged 24%. The company said Friday it plans to develop potential therapies for the treatment and prevention of hantavirus infections using its portfolio of antiviral drug candidates targeting negative-strand RNA viruses.Novo Nordisk  saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg reported, citing data from market researcher Pharmarack. Novo added 0.2%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2271345857.HKD","LU0158827781.USD","LU2089284900.SGD","LU2023251221.USD","TRAW","LU0107464264.USD","LU0471298694.HKD","LU0154236417.USD","LU1236620834.HKD","LU1721429402.USD","LU2308191902.HKD","NVO","LABU","NVOH","IBB","BK4137","ZTS","BK7104","LU0158827948.USD","LU0289739699.SGD","BK4534","LU0471298777.SGD","BK4585","BK4581","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2360106947.USD","LU0029874061.USD","XLV","LU0079474960.USD","IE00B19Z9505.USD","BK4599","NVOX","LU0128526141.USD","LU1236620750.USD","LU1941712264.USD","LU1093756325.SGD","LU1941712348.USD","LU2028103732.USD","GB00BDT5M118.USD","LU0385154629.USD","LU0345774631.USD","LU1059921491.USD","BK4588","LU0345774391.USD","LU1093756168.USD","LU2111349929.HKD","BK4532","XBI","IE00BKVL7J92.USD","LU2089283258.USD","BK4007","LU1721429741.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634663466","title":"There are no hantavirus treatments. The deadly cruise-ship outbreak is a 'wake-up call' to develop some.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634663466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634663466?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:43","pubTimestamp":1778262180,"startTime":"0","endTime":"0","summary":"\"Maybe this is a wake-up call,\" said Kartik Chandran, a hantavirus researcher and a professor of microbiology and immunology at the Albert Einstein College of Medicine in New York.Back in 2019, a group of scientists took $22 million from the U.S. government and developed a monoclonal antibody that appears to work in the lab against the Andes virus - which is responsible for the cruise-ship outbreak that has killed three people so far - and two other hantaviruses.But the project has since stalled. Without additional funding from the government or a nonprofit, the researchers don't have the money to put the experimental treatment through its first human studies, according to Kartik Chandran, the project's leader and a professor of microbiology and immunology at the Albert Einstein College of Medicine in New York. That's a necessary next step to bring any treatment to market.For the scientists who study hantaviruses, particularly the Andes virus, the outbreak doesn't come as a surprise. S","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633127456","title":"Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2633127456","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633127456?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:26","pubTimestamp":1778243203,"startTime":"0","endTime":"0","summary":"Traws Pharma  plans to develop potential therapies for the treatment and prevention of hantavirus infections using its existing portfolio of antiviral drug candidates targeting negative-strand RNA viruses, the company said Friday.The company said the candidates have demonstrated activity against negative-strand virus replication and could be developed as standalone or combination therapies.Traws also plans to leverage its existing development infrastructure and proprietary chemical libraries to identify optimal Hantaan virus treatments.There are currently no approved treatments for Hantaan pulmonary disease, a rodent-borne infection with human fatality rates ranging from 30% to 50%, the company said.Traws Pharma shares were up 33% in recent premarket activity on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455140","title":"BRIEF-Traws Pharma To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455140","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455140?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:02","pubTimestamp":1778241729,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma To Advance Potential Clinical Candidates For The Treatment Of Hantavirus InfectionsMay 8 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA TO ADVANCE POTENTIAL CLINICAL CANDIDATES FO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA3J1VWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633533174","title":"Traws Pharma targets rapid advancement of clinical candidates for hantavirus treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633533174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633533174?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239848,"startTime":"0","endTime":"0","summary":"Traws Pharma set plans to rapidly advance potential clinical candidates for treatment and prevention of hantavirus disease, targeting Hantaan virus.Strategy relies on screening its existing antiviral portfolio already tested against negative-strand RNA virus replication, with candidates potentially used as monotherapy or in combinations to reach required potency.Program includes use of its drug development and virus testing network to select lead candidates, alongside access to proprietary chemical libraries to identify additional compounds.Company framed effort as an emergency development and stockpiling initiative, citing lack of approved treatments for Hantaan pulmonary disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL3RxCV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","TRAW","IE00BN0W2W23.USD","BK4588","LU2210149790.SGD","BK4007","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4585","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633802453","title":"Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2633802453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633802453?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA3J1VWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631720556","title":"OrbiMed Advisors acquires 597,729 Traws Pharma shares worth $998,207","url":"https://stock-news.laohu8.com/highlight/detail?id=2631720556","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631720556?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:42","pubTimestamp":1777426955,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors disclosed an increase in its stake in Traws Pharma to 1,203,250 shares through an indirect holding.Filing showed purchase of 597,729 shares at USD 1.67 per share.OrbiMed also reported warrant positions covering up to 2,988,645 shares, with an exercise price of USD 1.67.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLycHS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors acquires 597,729 Traws Pharma shares worth $998,207","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230792","title":"Traws Pharma Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230792?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:39","pubTimestamp":1776285576,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc reports results for the quarter ended December 31 - Earnings SummaryTraws Pharma Inc TRAW.OQ reported quarterly adjusted earnings of 63 cents per share for the quarter ended December ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL8N40Y244:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627823052","title":"Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2627823052","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627823052?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:25","pubTimestamp":1776284738,"startTime":"0","endTime":"0","summary":"Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51845479/traws-pharma-q4-eps-0-71-misses-0-69-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627965237","title":"Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627965237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627965237?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283319,"startTime":"0","endTime":"0","summary":"Traws Pharma swung to net income of USD 9.2 million, versus a net loss of USD 166.5 million a year earlier.Revenue climbed to USD 2.8 million; the increase was due to recognition of deferred revenue following termination of the Symbio license agreement.Operating loss narrowed to USD 17.9 million from USD 142.4 million.PIPE financing for up to USD 60 million closed April 15, including USD 10 million upfront, with additional proceeds tied to milestone-based and three-year warrants.Cash and cash equivalents totaled USD 3.8 million at Dec. 31, 2025; financing and existing cash expected to fund operations into Q1 2027, including planned Phase 2a single-dose influenza human challenge trial for tivoxavir marboxil in Q2 2026 pending MHRA approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL89wgFv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4007","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","TRAW","BK4585","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627770281","title":"Traws Pharma Announces up to $60 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627770281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627770281?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA5FJNRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627284887","title":"Traws Pharma Inc - Financing Advances Co's Influenza Program Through a Human Challenge Trial for Tivoxavir Marboxil in United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2627284887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627284887?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA5FJNRR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627848982","title":"Press Release: Traws Pharma Announces Up to $60 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627848982","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627848982?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":"-- Financing led by Sirenia Capital Management LP advances Traws Pharma's. influenza program through a human challenge trial for tivoxavir marboxil. \"We are pleased to announce this financing and the support of existing and new investors,\" said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. \"The capital from this financing positions us to advance our influenza program through a human challenge trial in the UK while preserving access to additional capital as we achieve key development milestones.\". The financing was completed on April 15, 2026, with funding thereunder expected April 16, 2026, subject to the satisfaction of customary closing conditions. The terms of the financing are described in more detail in the Company's current report on Form 8-K to be filed in connection with the financing.Citizens JMP Securities, LLC and Tungsten Advisors LLC  acted as co-placement agents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627228128","title":"Traws Pharma Inc - Announces Pricing of Private Placement for 6 Mln Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627228128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627228128?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:05","pubTimestamp":1776254716,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y07A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627281190","title":"Traws Pharma prices unregistered $10 million PIPE at $1.67 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627281190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627281190?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:03","pubTimestamp":1776254627,"startTime":"0","endTime":"0","summary":"Traws Pharma announced a PIPE private placement expected to raise USD 10 million in gross proceeds at closing.Deal priced at USD 1.67 per share through sale of common stock or pre-funded warrants.Milestone-based Series A and Series B warrants could add about USD 20 million in gross proceeds if exercised.Series C warrant could add up to USD 30 million in gross proceeds if exercised over a three-year term.Proceeds earmarked to advance influenza program through a UK human challenge trial for tivoxavir marboxil.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securiti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL67rwhD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192165","title":"Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626192165?lang=en_us&edition=fundamental","pubTime":"2026-04-09 02:46","pubTimestamp":1775673991,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 3 for CFO Charles Nolan Parker, dated July 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLGbKRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624455849","title":"Traws Pharma delays annual report filing, seeks 15-day extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2624455849","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624455849?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990789,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 12b-25 to delay its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Filing delay tied to additional time needed to assess impact of potential financing on financial statements, including going-concern disclosures.Management reported no financing agreement in place as it works to address Nasdaq minimum stockholders’ equity requirement.Company expects to file Form 10-K within 15-day extension period allowed under SEC rules.Preliminary results point to revenue of $2.8 million; net income seen at about $9.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLb6NVn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622297758","title":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622297758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622297758?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:32","pubTimestamp":1774614726,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview Traws Pharma Inc TRAW.OQ TRAW.O is expected to  show a fall in quarterly revenue when it reports  results on March 30 (est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612400625","title":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400625","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400625?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:17","pubTimestamp":1771507073,"startTime":"0","endTime":"0","summary":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold** Shares of Traws Pharma TRAW.O down 20.81% at $1.58 premarket** Co says the U.S. FDA placed on clinical hold its investigational new drug application for tivoxavir marboxil, a single oral tablet for prevention of seasonal influenza** Adds that FDA flagged concerns \"with the mutagenicity data package\" for drug in application** Also says it filed the application to allow the government's biomedical research unit to fully review its bid for inclusion in the strategic stockpile for avianflu treatment** Clinical hold does not directly impact ongoing and planned studies outside of the United States; working to mitigate issue in clinical development plan - TRAW  ** TRAW shares up 74.3% YTD       ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trawspharma.com","stockEarnings":[{"period":"1week","weight":0.4631},{"period":"1month","weight":0.3974},{"period":"3month","weight":0.1122},{"period":"6month","weight":0.1179},{"period":"1year","weight":0.5571},{"period":"ytd","weight":0.9292}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.179894},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.08728},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.040526},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.139367},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.014961},{"month":6,"riseRate":0.75,"avgChangeRate":0.06745},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019463},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.120142},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.103896},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.080722},{"month":11,"riseRate":0.461538,"avgChangeRate":-0.058331},{"month":12,"riseRate":0.307692,"avgChangeRate":0.009577}],"exchange":"NASDAQ","name":"TRAWS PHARMA","nameEN":"TRAWS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRAWS PHARMA,TRAW,TRAWS PHARMA股票,TRAWS PHARMA股票老虎,TRAWS PHARMA股票老虎国际,TRAWS PHARMA行情,TRAWS PHARMA股票行情,TRAWS PHARMA股价,TRAWS PHARMA股市,TRAWS PHARMA股票价格,TRAWS PHARMA股票交易,TRAWS PHARMA股票购买,TRAWS PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction